Patent · US Active

Joint product comprising synephrine and topiramate

US9457008B2 · kind B2 · utility

0Cited by

1References

25Claims

0Family size

Assignee

INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY, ACADEMY OF MILITARY MEDICAL SCIENCES · CN

Inventors

Song Li · Beijing, CN
Chunsheng Gao · Beijing, CN
Wu Zhong · Beijing, CN
Yuli Wang · Tianjin, CN
Meiyan Yang · Beijing, CN
Li Shan · Beijing, CN
Xinbo Zhou · Beijing, CN
Zhibing Zheng · Beijing, CN
Xiaokui Wang · Beijing, CN

Key dates

Filing date	Mar 22, 2013
Grant date	Oct 4, 2016
Priority date	—
Expiry date	Mar 22, 2033

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K9/5047
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides a joint product comprising synephrine and topiramate, in which the synephrine or salt thereof is administered in form of rapid-release preparation, preferably rapid-release pellet, having daily dose of 2 mg to 25 mg, preferably 5 mg to 20 mg; the topiramate is administered in form of sustained-release or controlled-release preparation, preferably sustained-release pellet, having daily dose of 20 mg to 100 mg, preferably 23 mg to 92 mg. The composition is used for treatment of obesity or other diseases associated with obesity.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.